Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination

The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hamad Ali, Abdulmohsen Alterki, Sardar Sindhu, Barrak Alahmad, Maha Hammad, Salman Al-Sabah, Mohammad Alghounaim, Mohammad H. Jamal, Ali Aldei, Mohammad J. Mairza, Maitham Husain, Sriraman Deverajan, Rasheed Ahmad, Preethi Cherian, Irina Alkhairi, Abdullah Alkandari, Jehad Abubaker, Mohamed Abu-Farha, Fahd Al-Mulla
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 diabetes mellitus type 2 vaccine mRNA vaccine BNT162b2 T2D Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/1e20e1ab130b4508b7d668fccca55432
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination

Ejemplares similares